摘要
目的系统评价豨莶通栓制剂联合西药治疗脑梗死的临床疗效和安全性。方法检索中国知识资源总库(CNKI)、中国学术期刊数据库(万方数据)、中文科技期刊数据库(重庆维普)、中国生物医学文献系统(CBM)和PubMed建库至2021年12月31日有关豨莶通栓制剂联合西药治疗脑梗死的临床RCT研究。由2名研究人员分别独立提取文献基本资料和进行方法学质量评价后,采用RevMan 5.4软件进行meta分析。结果共纳入文献9篇,涉及患者988例,其中试验组505例、对照组483例。Meta分析结果显示,豨莶通栓制剂联合西药治疗脑梗死临床总有效率高于常规西药治疗[RR(95%CI)为1.20(1.13,1.27),P<0.05];在改善美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力评分(Barthel指数)、纤维蛋白原方面效果亦优于常规西药治疗[MD(95%CI)为-3.21(-4.45,-1.97),P<0.05;MD(95%CI)为11.83(10.66,13.00),P<0.05;MD(95%CI)为-0.95(-1.36,-0.54),P<0.05]。使用豨莶通栓制剂联合西药治疗后,出现的不良反应主要有头晕恶心、消化不良、皮疹、颜面潮红等,2组用药安全性比较,差异无统计学意义[RR(95%CI)为1.50(0.75,3.01),P>0.05]。结论在常规西药基础上加用豨莶通栓制剂可提高脑梗死治疗效果,有效改善患者神经功能缺损症状、提高其日常生活自理能力,促进预后康复,且不会提高不良反应发生率,但仍需大样本、高质量研究支持结论。
Objective To systematically evaluate the clinical efficacy and safety of Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction.Methods All RCTs about Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction were retrieved from CNKI,Wanfang Database,VIP database,PubMed and CBM.The search period was from the database establishment to December 31,2021.Two researchers independently extracted the basic literature data and evaluated the methodological quality,then used RevMan5.4 software for meta-analysis.Results Totally 9 articles were included,involving a total of 988 patients,including 505 cases in the observation group and 483 cases in the control group.Meta-analysis showed that the total effective rate of Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction was higher than that of conventional Western medicine[RR=1.20,95%CI(1.13,1.27),P<0.05].At the same time,the effect of NIHSS score,Barthel score and FIB were better than those of conventional Western medicine[respectively:MD=-3.21,95%CI(-4.45,-1.97),P<0.05;MD=11.83,95%CI(10.66,13.00),P<0.05;MD=-0.95,95%CI(-1.36,-0.54),P<0.05].After treatment with Xixian Tongshuan Capsules/Pills combined with Western medicine,the adverse reactions mainly included dizziness,nausea,indigestion,rash,facial blushing,etc.There was no statistically significant difference in safety between the two groups[RR=1.50,95%CI(0.75,3.01),P>0.05].Conclusions Under the treatment of conventional Western medicine,the addition of Xixian Tongshuan Capsules/Pills can improve the clinical efficacy of cerebral infarction treatment,effectively improve the symptoms of neurological impairment,improve the ability of daily life,and promote the prognosis and recovery,and without increasing the incidence of adverse reactions.However,large sample and high quality studies are still needed to support the conclusion.
作者
蒋玉倩
张令霖
连新福
李先涛
谢蓉
白永军
Yuqian Jiang;Linglin Zhang;Xinfu Lian;Xiantao Li;Rong Xie;Yongjun Bai(Department of Encephalopathy and Internal Medicine,Zhuhai Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine,Zhuhai 519015,China;Department of Science and Education,South University of Science and Technology Hospital,Shenzhen 518055,China;School of Basic Medical Science,Guangzhou University of Chinese Medicine,Guangzhou 510006,China)
出处
《国际中医中药杂志》
2023年第6期755-759,共5页
International Journal of Traditional Chinese Medicine
基金
国家重点基础研究发展(973)计划项目(2014CB542901)
广东省中医药管理局科研项目(20171248)。
关键词
中成药
豨莶通栓制剂
西药
脑梗塞
临床疗效
META分析
Chinese patent drugs
Xixian Tongshuan Capsule/Pill
Western medicine
Brain infarction
Clinical efficacy
Meta-analysis
